Grant M. Gallagher

Here is a look at infectious disease-related FDA news from the week of May 10, 2020.

A summary of Contagion's top stories for May 15, 2020.

Elizabeth Leung, PharmD, shares SIDP's educational efforts surrounding COVID-19 treatment.

A new first-of-its-kind global registry aimed at sharing real-time information on hospital care and ICU admissions could expand the scope of SARS-CoV-2 research.

A briefing on the day's top stories.

In an in vitro reconstituted human respiratory epithelium model, the investigational drug inhibited replication of the novel coronavirus.

Vaccine candidate mRNA-1273 has been granted Fast Track designation by the US FDA.

A summary of today's top stories.

A quick summary of the day's infectious disease headlines.

Conversations about PrEP with a clinician are the least common among adolescents with the greatest risk for HIV.

A brief summary of our daily coverage.

Here is a look at some of the US FDA authorizations in the month of May so far.

Moderna hopes to initiate phase 2 and late stage studies of its vaccine candidate, mRNA-1273, against COVID-19.

A quick summary of our daily COVID-19 coverage.

It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.

Investigators say they consider cefiderocol a candidate for therapeutic drug monitoring.

As children born in 2015-2016 with congenital Zika syndrome age, investigators are gradually able to assess neurodevelopmental outcomes.

The wearable technology is now authorized to monitor patients for changes in QT interval. Investigational drugs being administered to COVID-19 patients, such as chloroquine and hydroxychloroquine, can cause prolongation of QT intervals and life-threatening arrhythmias.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A round up of the top infectious disease news from April.

Disparate reimbursement policies disincentivize clinicians from vaccinating adults with lower incomes.

Treatment with remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.

The SIMPLE trial appears to have demonstrated that patients receiving the 5-day dose duration achieved similar improvement in clinical status compared to patients who received the 10-day dosing duration.

A daily round up of our COVID-19 coverage.

Over half of residents with positive test results were asymptomatic at the time of testing, during a recent survey.

Tune in for a daily COVID-19 update.

The FDA released a drug safety communication cautioning against the use of hydroxychloroquine or chloroquine for COVID-19 outside of hospital and clinical trial settings.

The authors of the review recommend the continued use of MMR vaccines on a mass scale.

Stephen Klasko, MD, MBA, CEO of Thomas Jefferson University Hospitals, discusses what COVID-19 has taught hospitals about preparing for pandemics.

Listen in for a daily COVID-19 news roundup.